tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Grinyó JM and Petruzzelli S Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. 2014 Expert Rev Clin Immunol pmid:25407098
Zaltzman JS et al. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. 2014 Transpl. Int. pmid:25160518
Weng LC et al. Association between use of FK506 and prevalence of post-transplantation diabetes mellitus in kidney transplant patients. 2014 Transplant. Proc. pmid:24656004
Gérard C et al. Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. 2014 AAPS J pmid:24526611
Mocchegiani F et al. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. 2014 Ann. Transplant. pmid:25347718
Filler G Finding the optimal therapeutic window for tacrolimus. 2014 Pediatr Transplant pmid:25345999
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Hinchliffe E et al. Therapeutic drug monitoring of ciclosporin A and tacrolimus in heart lung transplant patients using dried blood spots. 2014 Ann. Clin. Biochem. pmid:23939194
Isoda K et al. The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. 2014 Intern. Med. pmid:24990333
Buendia JA et al. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis. 2014 Ther Drug Monit pmid:24378577
Eid L et al. Late acute rejection: incidence, risk factors, and effect on graft survival and function. 2014 Pediatr Transplant pmid:24372967
Basu B Ofatumumab for rituximab-resistant nephrotic syndrome. 2014 N. Engl. J. Med. pmid:24670185
Fukushima A et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. 2014 Br J Ophthalmol pmid:24695688
Schellekens J et al. The Maastricht Transplant Center: clinical setting and epitope searches in HLA class II molecules: does the structural localization of a polymorphic site contribute to its immunogenicity? 2014 Transpl. Immunol. pmid:25240735
Parks AC et al. Long-term clearance of linear porokeratosis with tacrolimus, 0.1%, ointment. 2014 JAMA Dermatol pmid:24553841
Xu C et al. Tacrolimus reversibly reduces insulin secretion, induces insulin resistance, and causes islet cell damage in rats. 2014 Int J Clin Pharmacol Ther pmid:24755137
Caraveo G et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25122673
Gajanayake T et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. 2014 Sci Transl Med pmid:25122638
Gionchetti P and Rizzello F IBD. Sequential rescue therapy in steroid-refractory ulcerative colitis. 2014 Nat Rev Gastroenterol Hepatol pmid:25023033
Shimizu M et al. Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. 2014 Rheumatology (Oxford) pmid:25065006
Marits P et al. Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay. 2014 Clin. Immunol. pmid:24909732
Uesugi M et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. 2014 Pharmacogenet. Genomics pmid:24911663
Al-Harbi NO et al. Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue. 2014 Biomed Res Int pmid:24987695
Saracino A et al. Multidrug-resistance 1 gene single-nucleotide polymorphisms do not influence long-term graft survival after kidney transplantation. 2014 Transplant. Proc. pmid:25242754
Zhu H et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF‑1α expression in vivo. 2014 Mol Med Rep pmid:24912495
Van Laecke S et al. The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. 2014 Transpl. Int. pmid:24909487
Trkulja V et al. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. 2014 Ther Drug Monit pmid:24518562
Sánchez L et al. Topical tacrolimus for recurrent penile Crohn's disease. 2014 J Crohns Colitis pmid:24815787
Reynolds BC et al. Use of belatacept to maintain adequate early immunosuppression in calcineurin-mediated microangiopathic hemolysis post-renal transplant. 2014 Pediatr Transplant pmid:24815506
Wang J and Fan H [Assessment of P70S6 kinase phosphorylation after liver transplantation by phospho-flow cytometry]. 2014 Zhonghua Yi Xue Za Zhi pmid:25623311
Hsiao FY and Hsu WW Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study. 2014 Int Urol Nephrol pmid:24009082
Heilman RL et al. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation. 2013 Sep-Oct Clin Transplant pmid:23924146
Benoit S and Hamm H Psoriasis from a prosthesis: unusual Koebner phenomenon in a girl with autoamputation of the leg. 2013 Sep-Oct Pediatr Dermatol pmid:23360396
Zahdi MR et al. Erosive pustular dermatosis of the scalp successfully treated with oral prednisone and topical tacrolimus. 2013 Sep-Oct An Bras Dermatol pmid:24173187
Riva N et al. [Pharmacovigilance of calcineurin inhibitor in peidatric kidney and liver transplantation]. 2013 Nov-Dec Farm Hosp pmid:24256007
Brodrick B et al. Influence of treatments on prognosis for vulvar lichen sclerosus: facts and controversies. 2013 Nov-Dec Clin. Dermatol. pmid:24160287
Bloom RD et al. A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. 2013 Nov-Dec Clin Transplant pmid:24118450
Labirua-Iturburu A et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. 2013 May-Jun Clin. Exp. Rheumatol. pmid:23465087
Chen SY et al. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study. 2013 May-Jun Clin Transplant pmid:23432535
Ramirez CB et al. Completely steroid-free immunosuppression in liver transplantation: a randomized study. 2013 May-Jun Clin Transplant pmid:23621629
Krishna N et al. Tacrolimus-induced paranoid delusions and fugue-like state. 2013 May-Jun Gen Hosp Psychiatry pmid:22959421
He L et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. 2013 May-Jun J. Nephrol. pmid:22956434
Kanzelmeyer NK et al. Correlations with six-month protocol biopsy findings in pediatric transplant recipients on low- and regular-dose CNI regimens. 2013 Mar-Apr Clin Transplant pmid:23414365
Tiwari R et al. Enhancements in healthcare information technology systems: customizing vendor-supplied clinical decision support for a high-risk patient population. 2013 Mar-Apr J Am Med Inform Assoc pmid:22813760
Albekairy A et al. Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. 2013 Mar-Apr Saudi J Gastroenterol pmid:23481136
LaMattina JC et al. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. 2013 Mar-Apr Clin Transplant pmid:23294013
Alfson ED et al. Lysis of catatonic withdrawal by propofol in a bone-marrow transplant recipient with adenovirus limbic encephalitis. 2013 Mar-Apr Psychosomatics pmid:22705183
Yoshida EM et al. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. 2013 Mar-Apr Ann Hepatol pmid:23396740
Castillo G et al. [Acute cellular rejection in a liver transplantation patient due to changing the brand of a generic immunosuppressant]. 2013 Jul-Sep Rev Gastroenterol Mex pmid:23866966
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Zhao YJ et al. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis. 2013 Jul-Aug Transplant. Proc. pmid:23953533
Weiler N et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? 2013 Jul-Aug Transplant. Proc. pmid:23953543
Stringa P et al. Ischemic preconditioning and tacrolimus pretreatment as strategies to attenuate intestinal ischemia-reperfusion injury in mice. 2013 Jul-Aug Transplant. Proc. pmid:23953566
Tachibana A et al. Repopulation of the immunosuppressed retrorsine-treated infant rat liver with human hepatocytes. 2013 Jul-Aug Xenotransplantation pmid:23683097
Favi E et al. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial. 2013 Jul-Aug Clin Transplant pmid:23710603
Eberlin M et al. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. 2013 Jul-Aug Transplant. Proc. pmid:23726723
Satyanarayan HS et al. Efficacy and tolerability of combined treatment with NB-UVB and topical tacrolimus versus NB-UVB alone in patients with vitiligo vulgaris: a randomized intra-individual open comparative trial. 2013 Jul-Aug Indian J Dermatol Venereol Leprol pmid:23760325
Babalola O and Strober BE Treatment of atopic dermatitis in pregnancy. 2013 Jul-Aug Dermatol Ther pmid:23914886
Conti R et al. Jessner-Kanof disease: two effective and sure therapeutic options. 2013 Jul-Aug Dermatol Ther pmid:23914897
Chakkera HA et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375287
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Yao B et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. 2013 Jan-Feb Transplant. Proc. pmid:23375298
Miyazaki T et al. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375323
Chang HY et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. 2013 Jan-Feb Transplant. Proc. pmid:23375324
Al Nahdi N et al. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. 2013 Jan-Feb Ann Hepatol pmid:23293209
Seco-Melantuche R et al. [Incidence of drug-induced thrombocytopenia in hospitalized patients]. 2013 Jan-Feb Farm Hosp pmid:23461497
Rao V et al. A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus. 2013 Jan-Feb Transplant. Proc. pmid:23267806
Langone A et al. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry. 2013 Jan-Feb Clin Transplant pmid:22861144
Shiba H et al. Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation. 2013 Apr-Jun Int Surg pmid:23701152
Adamu B et al. New-onset diabetes after renal transplantation: a case series as seen in a Nigerian kidney transplant population. 2013 Apr-Jun Niger J Clin Pract pmid:23563475
Cangemi G et al. Comparison of antibody-conjugated magnetic immunoassay and liquid chromatography-tandem mass spectrometry for the measurement of cyclosporine and tacrolimus in whole blood. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755756
Landy J and Hart AL Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. 2013 Aliment. Pharmacol. Ther. pmid:23336680
Heavner MS et al. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. 2013 Am J Health Syst Pharm pmid:23943182
Siepmann D et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. 2013 Dermatology (Basel) pmid:24281309
Øzbay LA et al. The effects of calcineurin inhibitors on prostanoid synthesis: a randomized cross-over study in healthy humans. 2013 Transpl. Int. pmid:23190385
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Tempestilli M et al. Low plasma concentrations of albumin influence the affinity column-mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation. 2013 Ther Drug Monit pmid:23191996
Ricciardelli I et al. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. 2013 Am. J. Transplant. pmid:24266973
Chen YP et al. [The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis]. 2013 Zhonghua Nei Ke Za Zhi pmid:24266997
Ogawa K et al. A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. 2013 Xenobiotica pmid:23153054
Zuo XC et al. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. 2013 Drug Metab. Pharmacokinet. pmid:23438946
Barraclough KA et al. A differential impact of mycophenolic acid, prednisolone, and tacrolimus exposure on sCD30 levels in adult kidney transplant recipients. 2013 Ther Drug Monit pmid:23503451
Kim BR et al. A case of tacrolimus-induced supraventricular arrhythmia after kidney transplantation. 2013 Sao Paulo Med J pmid:23903271
Sánchez Ferreiro AV and Muñoz Bellido L [Tacrolimus in the treatment of atopic kerato-conjunctivitis]. 2013 Arch Soc Esp Oftalmol pmid:23886369
Kapoor K et al. Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70. 2013 J. Biol. Chem. pmid:24064216
de Heus C et al. Analysis of EGF receptor oligomerization by homo-FRET. 2013 Methods Cell Biol. pmid:24143984
Radu CD et al. Cotton-made cellulose support for anti-allergic pajamas. 2013 Carbohydr Polym pmid:23618296
First MR et al. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. 2013 Transplantation pmid:23619735
Lehner GM and Linek M A case of vesicular cutaneous lupus erythematosus in a Border collie successfully treated with topical tacrolimus and nicotinamide-tetracycline. 2013 Vet. Dermatol. pmid:24118370
Zhu L et al. A limited sampling strategy for tacrolimus in liver transplant patients. 2013 Int J Clin Pharmacol Ther pmid:23547852
Saint-Marcoux F et al. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. 2013 Ther Drug Monit pmid:23666572
Fan L et al. Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. 2013 Int Urol Nephrol pmid:22684795
Dufty NE et al. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. 2013 J. Antimicrob. Chemother. pmid:23249840
Kymionis GD et al. Treatment of superior limbic keratoconjunctivitis with topical tacrolimus 0.03% ointment. 2013 Cornea pmid:23770977
Yan L et al. Immunomodulatory effectiveness of tacrolimus in preventing epidural scar adhesion after laminectomy in rat model. 2013 Eur. J. Pharmacol. pmid:23220162
Kurasawa T et al. Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. 2013 Intern. Med. pmid:23676603
Güngör S et al. Squamous cell carcinoma on the lower lip after using topical calcineurin inhibitor. 2013 J Dtsch Dermatol Ges pmid:23763692
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
Kitahama M et al. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. 2013 Mod Rheumatol pmid:22975732
Chhabra D et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. 2013 Am. J. Transplant. pmid:24007570